ReviewJournal of psychiatry & neuroscience : JPN2007
Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?
Review in Journal of psychiatry & neuroscience : JPN, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 4 syntheses or guidelines pooled it, 203 citations in OpenAlex.
- Cannabis use among cancer patients and survivors in the United States: a systematic review.JNCI cancer spectrum · 2024Pooled it
- Suicidality risk after using cannabis and cannabinoids: An umbrella review.Dialogues in clinical neuroscience · 2023Pooled it
- Effects of cannabis on impulsivity: a systematic review of neuroimaging findings.Current pharmaceutical design · 2014Pooled it
- The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.Schizophrenia bulletin · 2012Pooled it
- Acute effects of ΔPsychopharmacology · 2022Trial
- Sensory gating in tobacco-naïve cannabis users is unaffected by acute nicotine administration.Psychopharmacology · 2022Trial
- Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.Psychopharmacology · 2011Trial
- Memory impairment and chronic high-dose Δ9-THC/cannabis exposure: a narrative review of molecular mechanisms underlying neurotoxic effects.Psychopharmacology · 2026Review
- Alterations in self-reported sensory gating and interoception in individuals frequently using cannabis.The American journal of drug and alcohol abuse · 2024Article
- Does cannabis affect cognitive functioning in patients with schizophrenia?Schizophrenia research. Cognition · 2024Article
- Article
- The effect of schizophrenia risk factors on mismatch responses in a rat model.Psychophysiology · 2023Article
- Neurocognitive moderation of repetitive transcranial magnetic stimulation (rTMS) effects on cannabis use in schizophrenia: a preliminary analysis.Schizophrenia (Heidelberg, Germany) · 2022Article
- Article
- Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs.Frontiers in psychiatry · 2021Review
- Quality of Life and a Surveillant Endocannabinoid System.Frontiers in neuroscience · 2021Review
- Chronic Use of Synthetic Cannabinoids Is Associated With Impairment in Working Memory and Mental Flexibility.Frontiers in psychiatry · 2020Article
- Dysregulation as a correlate of cannabis use and problem use.Addictive behaviors · 2019Article
- Deficient Functioning of Frontostriatal Circuits During the Resolution of Cognitive Conflict in Cannabis-Using Youth.Journal of the American Academy of Child and Adolescent Psychiatry · 2019Article
- Early Somatosensory Processing Over Time in Individuals at Risk to Develop Psychosis.Frontiers in psychiatry · 2019Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there is a lot of interest in cannabis use as a risk factor for the development of schizophrenia. Cognitive dysfunction associated with long-term or heavy cannabis use is similar in many respects to the cognitive endophenotypes that have been proposed as vulnerability markers of schizophrenia. In this overview, we examine the similarities between these in the context of the neurobiology underlying cognitive dysfunction, particularly implicating the endogenous cannabinoid system, which plays a significant role in attention, learning and memory, and in general, inhibitory regulatory mechanisms in the brain. Closer examination of the cognitive deficits associated with specific parameters of cannabis use and interactions with neurodevelopmental stages and neural substrates will better inform our understanding of the nature of the association between cannabis use and psychosis. The theoretical and clinical significance of further research in this field is in enhancing our understanding of underlying pathophysiology and improving the provision of treatments for substance use and mental illness.
Indexed as
Identifiers
17245472PMC1764544W65866596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.